BRIEF-Intellia Therapeutics Q3 loss per share $?0.44 [Reuters]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Reuters
BRIEF-Intellia Therapeutics Q3 loss per share $?0.44? | Reuters Reuters Staff 1 Min Read Oct 31 (Reuters) - Intellia Therapeutics Inc: * Intellia therapeutics announces third quarter 2017 financial results * Q3 collaboration revenue $7.3 million versus $4.9 million * Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S * Says ?well-tolerated safety profile observed for CRISPR/Cas9 * Qtrly loss per share $?0.44 * Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2017 Reuters. All Rights Reserved. BRIEF-Intellia Therapeutics Q3 loss per share $?0.44 Oct 31 (Reuters) - Intellia Therapeutics Inc: * Intellia therapeutics announces third quarter 2017 financial results * Q3 collaboration revenue $7.3 million versus $4.9 million * Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S * Says ?well-tolerated safety profile o
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- 2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]Yahoo! Finance
- Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]BNN Bloomberg
- Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/22/24 - Beat
NTLA
Sec Filings
- 4/16/24 - Form PRE
- 4/15/24 - Form 8-K
- 3/22/24 - Form 8-K
- NTLA's page on the SEC website